Ignite Creation Date:
2025-12-24 @ 11:49 AM
Ignite Modification Date:
2026-01-04 @ 12:38 PM
Study NCT ID:
NCT03036761
Status:
COMPLETED
Last Update Posted:
2021-04-21
First Post:
2017-01-27
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Interest of Auriculotherapy in Prophylaxis of Migraine and Headache in Patients With Migraines
Sponsor:
Hopital Foch
Organization:
Study Overview
Official Title:
Interest of Auriculotherapy in Prophylaxis of Migraine and Headache in Patients With Migraines
Status:
COMPLETED
Status Verified Date:
2021-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Migauric
Brief Summary:
The aim of the study is to show that auriculotherapy decreases the number of days with painful episodes of migraine and headache after 3 months of treatment
Detailed Description:
Prospective, multicenter, controlled and randomized study.
At the inclusion:
* initial assessment of migraine and headache attacks of the last 3 months with the migraine/headache/treatment diary;
* quality of life assessment (MIDAS questionnaire).
Patients are randomized in 2 groups (distribution 2/3 AUR+, 1/3 AUR-):
* AUR+: experimental group "Auriculotherapy". Patients benefit from 3 sessions of auriculotherapy at one month intervals.
* AUR-: control group. Patients do not benefit from auriculotherapy.
After 3 months, a visit of Algology is carried out :
* final assessment of migraine and headache attacks of the last 3 months with the migraine/headache/treatment diary;
* quality of life assessment (MIDAS questionnaire).
At the inclusion:
* initial assessment of migraine and headache attacks of the last 3 months with the migraine/headache/treatment diary;
* quality of life assessment (MIDAS questionnaire).
Patients are randomized in 2 groups (distribution 2/3 AUR+, 1/3 AUR-):
* AUR+: experimental group "Auriculotherapy". Patients benefit from 3 sessions of auriculotherapy at one month intervals.
* AUR-: control group. Patients do not benefit from auriculotherapy.
After 3 months, a visit of Algology is carried out :
* final assessment of migraine and headache attacks of the last 3 months with the migraine/headache/treatment diary;
* quality of life assessment (MIDAS questionnaire).
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2016-A01534-47 | OTHER | ANSM | View |